Compare NYAX & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NYAX | TNGX |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | N/A | N/A |
| Metric | NYAX | TNGX |
|---|---|---|
| Price | $45.07 | $10.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $46.25 | $12.00 |
| AVG Volume (30 Days) | 21.0K | ★ 3.0M |
| Earning Date | 11-19-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.63 | N/A |
| Revenue | ★ $369,938,000.00 | $66,501,000.00 |
| Revenue This Year | $29.84 | $53.01 |
| Revenue Next Year | $23.38 | N/A |
| P/E Ratio | $71.30 | ★ N/A |
| Revenue Growth | 26.84 | ★ 53.29 |
| 52 Week Low | $26.77 | $1.03 |
| 52 Week High | $52.46 | $11.20 |
| Indicator | NYAX | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 62.51 | 60.42 |
| Support Level | $42.24 | $9.90 |
| Resistance Level | $45.63 | $11.05 |
| Average True Range (ATR) | 1.28 | 0.72 |
| MACD | 0.50 | 0.08 |
| Stochastic Oscillator | 93.08 | 68.89 |
Nayax Ltd is an end-to-end retail technology platform for unattended commerce. It provides consumers with digital, cashless payments, and connected commerce experiences, enhancing consumer conversion and loyalty. Its platform addresses the entire unattended commerce value chain, including a payments infrastructure, a commerce software suite, a consumer engagement platform, and integrated POS devices. The company addresses a broad range of retail verticals, including all types of vending machines, coffee machines, unattended checkout counters, self-service kiosks, ticketing machines, car wash stations, gaming machines, amusement rides, laundromats, EV charging stations, and many more.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.